Diagnostic Characteristics and Metabolic Risk Factors of Cases with Polycystic Ovary Syndrome during Adolescence

Journal of Pediatric and Adolescent Gynecology

Volumn 28, Issue 2, 2015, Pages 78-83

  Siklar, Zeynep ^a   Berberoğlu, Merih ^a   Çamtosun, Emine ^a   Kocaay, Pinar ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Adolescents; Diagnosis; Polycystic ovary syndrome

Indexed keywords

DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTRADIOL; FLUTAMIDE; FOLLITROPIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYPROGESTERONE; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; METFORMIN; PRASTERONE SULFATE; PROLACTIN; PROTEIN C; PROTHROMBIN; TESTOSTERONE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADOLESCENT; ADOLESCENT DISEASE; ANOVULATION; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHILD; DISEASE ASSOCIATION; DYSLIPIDEMIA; ECHOGRAPHY; FEMALE; HIRSUTISM; HUMAN; HYPERANDROGENISM; HYPERINSULINISM; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MENSTRUAL IRREGULARITY; METABOLIC PARAMETERS; METABOLIC SYNDROME X; OBESITY; ORAL CONTRACEPTION; OUTPATIENT DEPARTMENT; OVARY POLYCYSTIC DISEASE; PHENOTYPE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; THYROID DISEASE; TREATMENT DURATION; WAIST CIRCUMFERENCE; COMPLICATION; POLYCYSTIC OVARY SYNDROME; TURKEY;

ADOLESCENT; ANOVULATION; CHILD; FEMALE; HUMANS; HYPERANDROGENISM; PHENOTYPE; POLYCYSTIC OVARY SYNDROME; RISK FACTORS; TURKEY;

EID: 84926381622     PISSN: 10833188     EISSN: 18734332     Source Type: Journal    
DOI: 10.1016/j.jpag.2014.05.006     Document Type: Article

References (33)

1. Livadas S., Diamantia-Kandarakis E. Polycystic ovary syndrome: Definitions, phenotypes and diagnostic approach. Polycystic ovary syndrome. Novel Insights into causes and therapy. Front Horm res 2013, 40:1. Karger, Basel. Macut D, M. Pheifer, B. Yildiz (Eds.).
2. Azziz R., Woods K.S., Reyna R., et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004, 89:2745.
3. Zawadzki J.K., Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. Polycystic Ovary Syndrome 1992, Blackwell Scientific, Boston, 4:377-384. A. Dunaif, J.R. Givens, F.P. Haseltine (Eds.).
4. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004, 19:41. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group.
5. Consensus on women's health aspects of polycystic ovary syndrome (PCOS). Hum Reprod 2012, 27:14. Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group.
6. Nicandri K.F., Hoeger K. Diagnosis and treatment of polycystic ovarian syndrome in adolescents. Curr Opin Endocrinol Diabetes Obes 2012, 19:497.
7. Fraser I.S., Critchley H.O., Broder M., et al. The FIGO recommendations on terminologies and definitions for normal and abnormal uterine bleeding. Semin Reprod Med 2011, 29:383.
8. Centers for Disease Control and Prevention: Healthy Weight - it's not a diet, it's a lifestyle! Available: Accessed January 09, 2012. http://www.cdc.gov/healthyweight/assessing/bmi/childrens_bmi/about_childrens_bmi.html.
9. Hatipoglu N., Ozturk A., Mazicioglu M.M., et al. Waist circumference percentiles for 7- to 17-year-old Turkish children and adolescents. Eur J Pediatr 2008, 167:383.
10. Tümer N., Yalçinkaya F., Ince E., et al. Blood pressure nomograms for children and adolescents in Turkey. Pediatr Nephrol 1999, 13:438.
11. Marshall W.A., Tanner J.M. Variations in pattern of pubertal changes in girls. Arch Dis Child 1969, 44:291.
12. Ferriman D., Gallwey J. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961, 21:1440.
13. Roe A.H., Prochaska E., Smith M., et al. Using the androgen excess-PCOS society criteria to diagnose polycystic ovary syndrome and the risk of metabolic syndrome in adolescents. J Pediatr 2013, 162:937.
14. Barber T.M., Alvey C., Greenslade T., et al. Patterns of ovarian morphology in polycystic ovary syndrome: a study utilising magnetic resonance imaging. Eur Radiol 2010, 20:1207.
15. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412.
16. Kurtoğlu S., Hatipoğlu N., Mazicioğlu M., et al. Insulin resistance in obese children and adolescents: HOMA-IR cut-off levels in the prepubertal and pubertal periods. J Clin Res Pediatr Endocrinol 2010, 2:100.
17. Diagnosis and classification of diabetes mellitus. Diabetes Care 2013, 36(Suppl 1):S67. American Diabetes Association.
18. Alberti K.G., Zimmet P., Shaw J. IDF Epidemiology Task Force Consensus Group: The metabolic syndrome-a new worldwide definition. Lancet 2005, 366:1059.
19. Villa P., Rossodivita A., Sagnella F., et al. Ovarian volume and gluco-insulinaemic markers in the diagnosis of PCOS during adolescence. Clin Endocrinol (Oxf) 2013, 78:285.
20. Blank S.K., Helm K.D., McCartney C.R., et al. Polycystic ovary syndrome in adolescence. Ann N Y Acad Sci 2008, 1135:76.
21. Carmina E., Oberfield S.E., Lobo R.A. The diagnosis of polycystic ovary syndrome in adolescents. Am J Obstet Gynecol 2010, 203:201.e1.
22. Chen Y., Yang D., Li L., et al. The role of ovarian volume as a diagnostic criterion for Chinese adolescents with polycystic ovary syndrome. J Pediatr Adolesc Gynecol 2008, 21:347.
23. Raissouni N., Kolesnikov A., Purushothaman R., et al. Altered glucose disposition and insulin sensitivity in peri-pubertal first-degree relatives of women with polycystic ovary syndrome. Int J Pediatr Endocrinol 2012, 2012:14.
24. Barber T.M., Franks S. Genetics of polycystic ovary syndrome. Front Horm Res 2013, 40:28-39.
25. Williams R.M., Ong K.K., Dunger D.B. Polycystic ovarian syndrome during puberty and adolescence. Mol Cell Endocrinol 2013, 373:61.
26. Curi D.D., Fonseca A.M., Marcondes J.A., et al. Metformin versus lifestyle changes in treating women with polycystic ovary syndrome. Gynecol Endocrinol 2012, 28:182.
27. Catteau-Jonard S., Dewailly D. Pathophysiology of polycystic ovary syndrome: the role of hyperandrogenism. Front Horm Res 2013, 40:22-27.
28. Kauffman R.P., Baker T.E., Baker V.M., et al. Endocrine and metabolic differences among phenotypic expressions of polycystic ovary syndrome according to the 2003 Rotterdam consensus criteria. Am J Obstet Gynecol 2008, 198:670.e1.
29. Baptiste C.G., Battista M.C., Trottier A., et al. Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol 2010, 122:42.
30. Parkin L., Sharples K., Hernandez R.K., et al. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ 2011, 342:d2139.
31. FDA Drug Safety Communication: Safety review update of possible increased risk of blood clots with birth control pills containing drospirenone. Available: Accessed January 09, 2012. http://www.fda.gov/drugs/drugsafety/ucm273021.htm.
32. Plu-Bureau G., Maitrot-Mantelet L., Hugon-Rodin J., et al. Hormonal contraceptives and venous thromboembolism: an epidemiological update. Best Pract Res Clin Endocrinol Metab 2013, 27:25.
33. Goldstein L.B., Bushnell C.D., Adams R.J., et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011, 42:517. American Heart Association Stroke Council, Council on Cardiovascular NursingCouncil on Cardiovascular Nursing, Council on Epidemiology and PreventionCouncil on Epidemiology and Prevention, Council for High Blood Pressure ResearchCouncil for High Blood Pressure Research, Council on Peripheral Vascular Disease, and Interdisciplinary Council on Quality of Care and Outcomes ResearchCouncil on Peripheral Vascular Disease, and Interdisciplinary Council on Quality of Care and Outcomes Research.